Compare EPR Properties (EPR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Twist Bioscience Corp — how do they compare? EPR Properties trades at $61.69 (market cap $4.60B), while Twist Bioscience Corp trades at $93.31 (market cap $5.76B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and EPR Properties pays a 6.19% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| EPR | TWST | |
|---|---|---|
Market Cap | $4.60B | $5.76B |
Sector | Real Estate | Health |
52-Week High | $60.81 | $102.88 |
52-Week Low | $48.71 | $24.16 |
Enterprise Value | $7.66B | $5.69B |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $61.80, up 3.8% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $63.25. The REIT maintains strong profitability with a 39.93% net income margin and 10.68% ROE, supported by recent earnings beats and a strategic shift toward experiential assets like the $315 million Six Flags acquisition. Monthly dividends of $0.31 provide a steady income stream, with Q2 2026 earnings results due July 29, 2026.
Outlook remains positive due to high occupancy, dividend yield, and portfolio diversification, but risks include reliance on consumer spending and potential interest rate impacts. Analyst sentiment is mixed with a hold-heavy consensus, suggesting cautious optimism for income-focused investors amid stable fundamentals.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
